SciLifeLab Research Infrastructure Survey - Pandemic & Health Crisis Preparedness Inventory

SciLifeLab Research Infrastructure Survey – Pandemic & Health Crisis Preparedness Inventory

Survey to map the capabilities, capacity, and preparedness of SciLifeLab research infrastructure platforms in the context of future pandemics and health crises. The information will support coordinated outbreak response and ensure continuity of research activities.

Please note that the survey must be completed in one session. It is not possible to save your responses and return later to continue editing.

Section 1: General Information

Contact person *

Contact person

First Name

Last Name

Affiliation *

Platform Name *

Genomics

Clinical Genomics

Proteomics

Metabolomics and Exposomics

Spatial Biology

Cellular and Molecular Imaging

Integrated Structural Biology

Chemical Biology and Genome Engineering

Bioinformatics

DDD

Units *

Sites *

Section 2: Research Infrastructure Services and Availability Section

Please list the main research infrastructure services offered by your platform. *

Which of your services could be used to study or handle infectious agents? *

Please list relevant services

Please upload the provided Excel fil: List of services that could be used to study or handle infectious agents.xlsx *

Maximum file size: 52.43MB

Section 3: Involvement in COVID-19 Response

7. Was your platform involved in COVID-19-related research and/or services? *

Yes

7a. Brief description of activities (max 5 sentences): *

7b. Type of involvement (select all that apply): *

Collaborative research

Service provision

Scientific advice / expert support

Method development

Diagnostic analyses

Infrastructure support

Data analysis / bioinformatics

Training

IT infrastructure / data storage

Other:

7c. Units involved: *

To select several units: On Mac, hold the “Command” key. On PC, hold the “Ctrl” key.

e. Personnel effort involved (FTE): *

less than 0.5

between 0.5–1

between 1–2

between 3–5

more than 5

Specify thte type of involvment *

d. External collaborators involved (select all that apply): *

Academic (Sweden)

Academic (international)

Healthcare providers / hospitals

Public Health Agency of Sweden

Government agencies (specify)

Industry

International organisations (specify)

None

Other:

f. Active years during the pandemic: *

g. Duration of involvement: *

Less than 1 month

Between 1–3 months

Between 3–6 months

Between6–12 months

Between1–2 years

More than 2 years

Ongoing

Specify the Government Agencies *

Specify the international Organization *

Specify other collaborators *

8. Was any COVID-19-related work performed in a BSL-3 environment? (This includes work performed either directly by your platform or through collaborators. *

Yes

a. Who performed the BSL-3 work? (select all that apply) *

Platform personnel

Collaborators

Both

Other: ______

b. Describe the work requiring BSL-3 *

Max 2–3 sentences. (For example – Virus culture, Neutralisation assays, Infection experiments, Handling infectious material, etc):

Specify who performed the BSL-3 work *

c. Why was BSL-3 not used? *

Not required for the work performed

Not accessible to the platform

Other: ______

Specify why the BSL-3 was not used *

Section 4: Interest in BSL-3 access and Future Needs

9. Does your platform currently have access to BSL-3 facilities? *

Yes – direct

Yes – via collaboration

N/A

10. Do you have personnel trained for BSL-3 work?

Yes

N/A

11. Does your platform currently have active service or research projects that require BSL-3 access? *

Yes – ongoing

Yes – planned

Not sure

N/A

12. What is your platform’s interest and needs in accessing BSL-3 facilities in the future? *

High priority

Moderate priority

Low priority

No interest

Not sure

No need- N/A

Section 5: Work on Other Infectious Agents

13. Do you have protocols and capabilities for work with BSL-2-classified pathogens? *

Yes

Not sure

14. Have you worked with infectious agents (excluding COVID-19) since 2020? *

Yes

a. Which agents? *

b. What type of service or research activities? *

Sample preparation

Data collection

Data analysis

Interpretation

Method development

Scientific advice

Training

Diagnostic support

Other: ______

Specify the type of service of research activities *

c. Techniques used: *

d. Personnel effort (FTE): *

Less than 0.5

Between 0.5–1

Between 1–2

Between 3–5

More than 5

e. Is this service still available? *

Yes, fully

Yes, partially

Section 6: Current Operations

15.What types of samples does your platform primarily handle? *

e.g. DNA, RNA, serum, whole blood, tissues, cells, sequencing data, imaging data, etc. Indicate source if relevant)

16. Current maximum capacity (core activities): *

17. Main limitations to capacity and throughput: *

Staff

Equipment

Space

Funding

Permits / governance

Limited demand

Other: ______

Specify the main liminations *

18. Do you maintain sample collections or biobanking? *

yes (estimate size)

Please Estimate the size of the sample collection *

19. How do you manage documentation and traceability? *

Section 7: Preparedness and Response Capacity

20. In the event of a major outbreak of an infectious disease, what proportion of your platform’s total activities could be redirected to outbreak-related research or services (estimated)? *

a. 0%

b. 1–10%

c. 11–25%

d. 26–50%

e. 51–75%

f. >75%

g. Not sure

21. Key limiting factors *

Service not relevant

Permits / governance

Financial resources

Staff

Equipment

Consumables

Biosafety level

Other: ______

Specify key limiting factors *

22. In the event of future major outbreaks from infectious diseases, do you foresee that your platforms operations would face: *

Challenges

Opportunities

Both

Neither

23. Do you foresee changes in your activity during future outbreaks? *

☐ Yes

☐ No

☐ Not sure

Describe expected changes (Examples: similar to COVID-19, less affected, more affected, increased activity, decreased activity, etc.): *

24. Do you have procedures for handling and sharing data during crises? *

Yes

Partially

Not sure

a. Briefly describe: *

25. Does your Platforform or any units in the platform currently have any kind of internal preparedness plan (multiple options)? *

Yes – continuity plan

Yes – outbreak contribution plan

Interested in developing one

What are the Key components needed in a preparedness plan *

Section 8: Involvement and collaboration with the PLP-program

26. Do you currently have, or have previously had research and/or service collaborations within the PLP-network (multiple options)? *

Yes

Multiple collaborations

Not yet, but interested

Not relevant

27. Do you have involvements or collaborations with other national or international preparedness initiatives (not limited to pandemic preparedness)? *

Ongoing

Planned

Please specify the involvmnet and collaborations

Section 9: Reflections, Lessons Learned and future suggestions

29. Did you experience loss or disruption of services during COVID-19? *

Yes

Sselect all that apply: *

Personnel shortages

Lack of consumables/equipment

Funding issues

Lack of projects

Lack of samples

Restricted facility access

Other: ______

Specify loss or disruption of services during COVID-19 *

Section 10. In the event of new major outbreaks of an infectious disease, what is your expectations and suggestions for support from SciLifeLab?

For outbreak response: *

For research continuity: *

Any additional reflections or suggestions:

If you are human, leave this field blank.